Company Encyclopedia
View More
name
Noxopharm Ltd.
NOX.AU
News
View More

Noxopharm Achieves Milestone in Autoimmune Drug Development with HERACLES Trial Completion

Noxopharm Ltd. has successfully completed the HERACLES clinical trial for its autoimmune drug candidate SOF-SKN™, confirming its safety and tolerability at the highest dose. This milestone positions the company to explore SOF-SKN’s potential in treating autoimmune-related skin diseases. The global market for cutaneous lupus erythematosus, a target condition, is valued at over US$3.3 billion, indicating significant commercial potential for Noxopharm's innovations. Noxopharm is a clinical-stage biotech firm focused on developing novel treatments for cancer and inflammation.

Tip Ranks·
Tip Ranks·

Noxopharm Initiates First SOF-SKN™ Dose in HERACLES Trial

Noxopharm Ltd. has initiated the first dose of its drug candidate SOF-SKN™ in the HERACLES clinical trial, aimed at evaluating its safety for autoimmune diseases, particularly cutaneous lupus erythematosus. This milestone positions Noxopharm to potentially capitalize on the $3 billion global lupus market and expand into other autoimmune conditions. Noxopharm is a clinical-stage biotech company focused on innovative treatments for cancer and inflammation, utilizing its proprietary technology platforms.

Tip Ranks·
Tip Ranks·

Noxopharm Issues New Unquoted Equity Securities

Noxopharm Ltd. has announced the issuance of new unquoted equity securities, including UNL C Notes and options expiring in 2027. This move is part of a strategic effort to enhance the company's capital structure, which may influence shareholder value and future market strategies. The company's current market cap stands at A$26.01M, with a year-to-date price performance of -1.11% and a consensus rating of 'Buy'.

Tip Ranks·
Tip Ranks·

Noxopharm Faces Convertible Note Issuance Delay

Noxopharm Ltd. (AU:NOX) has announced a delay in issuing a $2.25 million convertible note to 4F Investments due to funding timing issues. The company, which focuses on cancer and inflammation treatments, needs to seek shareholder re-approval before proceeding. This situation underscores potential challenges in meeting regulatory requirements for listed companies.

Tip Ranks·
Tip Ranks·